公开(公告)号：US20240156823A1

公开(公告)日：2024-05-16

申请号：US18409125

申请日：2024-01-10

Applicant: Boehringer Ingelheim International GmbH

Inventor： Thomas KLEIN ,  Andreas DAIBER ,  Odd-Erik JOHANSEN ,  Michael MARK ,  Sanjaykumar PATEL ,  Hans-Juergen WOERLE

IPC: A61K31/522 ,  A61K31/155 ,  A61K31/397 ,  A61K31/4184 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/616 ,  A61K31/727 ,  A61K31/785 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  C07D473/06 ,  C07D473/12

CPC classification number: A61K31/522 ,  A61K31/155 ,  A61K31/397 ,  A61K31/4184 ,  A61K31/519 ,  A61K31/5377 ,  A61K31/616 ,  A61K31/727 ,  A61K31/785 ,  A61K38/26 ,  A61K38/28 ,  A61K45/06 ,  C07D473/06 ,  C07D473/12

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

公开(公告)号：US20230365564A1

公开(公告)日：2023-11-16

申请号：US18024721

申请日：2021-09-03

Applicant: Teon Therapeutics, Inc.

Inventor： Jiwen LIU ,  Drazen OSTOVIC ,  Sami KARABORNI

IPC: C07D473/06

CPC classification number: C07D473/06 ,  C07B2200/13

Abstract: Cocrystals of an adenosine A2B receptor antagonist, 3-ethyl-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-1H-pyrazol-4-yl)-3,7-dihydro-1H-purine-2,6-dione, methods of preparing the cocrystals, pharmaceutical compositions of the cocrystals, and uses of the cocrystals are disclosed.

公开(公告)号：US20230322782A1

公开(公告)日：2023-10-12

申请号：US18202993

申请日：2023-05-29

Applicant: Board of Regents, The University of Texas System

Inventor： Jean X. Jiang

IPC: C07D473/06 ,  A61K31/522 ,  A61P35/00 ,  C07D473/34

CPC classification number: C07D473/06 ,  A61K31/522 ,  A61P35/00 ,  C07D473/34

Abstract: Certain embodiments are directed to the use of chemical compounds that inhibit migration and growth of cancer cells.

公开(公告)号：US20190233423A1

公开(公告)日：2019-08-01

申请号：US16373971

申请日：2019-04-03

Applicant: Boehringer Ingelheim International GmbH

Inventor： Peter SIEGER ,  Dirk KEMMER ,  Peter KOHLBAUER ,  Thomas NICOLA ,  Martin RENZ

IPC: C07D473/06 ,  C07D473/04

CPC classification number: C07D473/06 ,  C07B2200/13 ,  C07D473/04

Abstract: The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament.

公开(公告)号：US20180291025A1

公开(公告)日：2018-10-11

申请号：US16008582

申请日：2018-06-14

Applicant: Boehringer Ingelheim International GmbH

Inventor： Frank HIMMELSBACH ,  Elke LANGKOPF ,  Matthias ECKHARDT ,  Roland MAIER

IPC: C07D473/04 ,  C07D519/00 ,  C07D473/06 ,  C07D473/08

CPC classification number: C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D519/00

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

公开(公告)号：US20180148451A1

公开(公告)日：2018-05-31

申请号：US15575315

申请日：2016-05-05

Applicant: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

Inventor： Linyun WU ,  Xiaoxin CHEN ,  Peng ZHANG ,  Xing LIU ,  Li ZHANG ,  Zhuowei LIU ,  Shuhui CHEN ,  Chaofeng LONG

IPC: C07D473/10 ,  C07D473/06 ,  C07D487/04 ,  C07D471/04 ,  C07D475/02

CPC classification number: C07D473/10 ,  C07D471/04 ,  C07D473/06 ,  C07D475/02 ,  C07D487/04

Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

公开(公告)号：US09938279B2

公开(公告)日：2018-04-10

申请号：US13858954

申请日：2013-04-09

Applicant: Han-Min Chen ,  Cheng-Yi Kuo ,  Chun-Fang Huang ,  Jiun-Tsai Lin

Inventor： Han-Min Chen ,  Cheng-Yi Kuo ,  Chun-Fang Huang ,  Jiun-Tsai Lin

IPC: C07D473/00 ,  C07D473/40 ,  C07D473/34 ,  C07D473/30 ,  C07D473/06 ,  C07D473/16 ,  C07D473/18 ,  C07D473/38 ,  C07D473/24 ,  C07D239/47 ,  C07D239/54 ,  C07D239/553 ,  C07D253/075 ,  C07D473/32

CPC classification number: C07D473/00 ,  C07D239/47 ,  C07D239/54 ,  C07D239/553 ,  C07D253/075 ,  C07D473/06 ,  C07D473/16 ,  C07D473/18 ,  C07D473/24 ,  C07D473/30 ,  C07D473/32 ,  C07D473/34 ,  C07D473/38 ,  C07D473/40

Abstract: The present invention relates to a method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) and the use of the compounds in the prevention or treatment of disease, including pre-diabetes, type 2 diabetes, syndrome X, metabolic syndrome and obesity.

公开(公告)号：US20180057495A1

公开(公告)日：2018-03-01

申请号：US15801442

申请日：2017-11-02

Applicant: Boehringer Ingelheim International GmbH

Inventor： Frank HIMMELSBACH ,  Elke LANGKOPF ,  Matthias ECKHARDT ,  Roland MAIER

IPC: C07D473/04 ,  C07D519/00 ,  C07D473/06 ,  C07D473/08

CPC classification number: C07D473/04 ,  C07D473/06 ,  C07D473/08 ,  C07D519/00

Abstract: The present invention relates to substituted xanthines of general formula wherein R1 to R3 are as defined herein, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).

公开(公告)号：US09879011B2

公开(公告)日：2018-01-30

申请号：US14384567

申请日：2013-03-12

Applicant: CADILA HEALTHCARE LIMITED

Inventor： Shriprakash Dhar Dwivedi ,  Ashok Prasad ,  Kuldeep Natwarlal Jain ,  Kumar Kamlesh Singh ,  Jitendra Maganbhai Gajera

IPC: C07D473/04 ,  C07D473/06

CPC classification number: C07D473/04 ,  C07D473/06 ,  Y10T428/2982

Abstract: The present invention relates to an amorphous form of linagliptin and processes for the preparation thereof. The invention also relates to a pharmaceutical composition comprising a therapeutically effective amount of an amorphous form of linagliptin and use of the composition for treatment of diabetes especially type-I or type-II, prediabetes or reduction of glucose tolerance.

公开(公告)号：US20180009809A1

公开(公告)日：2018-01-11

申请号：US15544056

申请日：2016-01-15

Applicant: Jean X. JIANG

Inventor： Jean X. JIANG

IPC: C07D473/06 ,  C07D473/34

CPC classification number: C07D473/06 ,  A61K31/522 ,  A61P35/00 ,  C07D473/34

Abstract: Certain embodiments are directed to non-hydrolysable ATP analogs and adenosine receptor antagonists that inhibit migration and growth of cancer cells.